DCGI gives final approval for Covid-19 vaccines of SII, Bharat Biotech

The Drugs Controller General of India (DCGI) has formally announced the final approval for Oxford-AstraZeneca “Covishield” and Bharat Biotech “Covaxin” vaccines against the coronavirus disease (Covid-19) for emergency use. CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines.

WARRIOR 4.0 | Banking Awareness Batch for SBI, RRB, RBI and IBPS Exams | Bilingual | Live Class

About Covishield:

The subject expert committee (SEC) under CDSCO had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.

About Covaxin:

Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Important takeaways for all competitive exams:

• Serum Institute of India CEO: Adar Poonawalla.
• Serum Institute of IndiaFounder: Cyrus S. Poonawalla.
• Serum Institute of IndiaFounded: 1966.
• Serum Institute of India Headquarters location: Pune.

Find More Sci-Tech News Here